Dipna Pharmachem Limited has strengthened its corporate governance structure by appointing two new independent directors and reconstituting its key board committees. The Board of Directors approved the appointment of Mr. Jitendra Pradipbhai Parmar and Mr. Manish Shrichand Bachani as Additional Non-Executive and Independent Directors effective May 11, 2026. These appointments aim to enhance the oversight capabilities of the board as the company continues its operations in the pharmaceutical sector.

The appointments were ratified during a board meeting held on May 11, 2026, at the company's registered office in Ahmedabad. Mr. Jitendra Pradipbhai Parmar brings over eight years of experience in corporate laws and financial management as a Practicing Company Secretary. Mr. Manish Shrichand Bachani holds a Bachelor of Commerce degree and possesses expertise in marketing management, business operations, and project management. Neither appointee is related to any existing director of the company.

Consequent to these inductions, the Board approved the reconstitution of three critical committees to ensure compliance with regulatory frameworks. The Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee have all been restructured effective May 11, 2026. Mr. Jitendra Pradipbhai Parmar has been designated as the Chairperson of all three committees.

The composition of the reconstituted committees includes the new independent directors alongside Mrs. Dipna Keyur Shah, who serves as a Non-Executive Non-Independent Director. The changes were communicated to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Committee Composition

Note: This structure applies to the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee.

Dipna Pharmachem Ltd has rescheduled its board meeting to July 2, 2026, to consider the audited financial results for the half year and year ended March 31, 2026. The meeting, initially convened on July 1, 2026, was adjourned to facilitate a thorough review of the financial performance and the accompanying Auditor's Report. The decision was taken during the board meeting held on July 1, 2026, at the company's registered office in Ahmedabad.

The rescheduled meeting will be held on July 2, 2026, at 4:00 P.M. at the registered office located at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad – 380 055. The primary agenda includes the discussion and approval of the audited financial results for the specified periods. Additionally, any other matter with the permission of the chairperson may be taken up for consideration.

The board meeting on July 1, 2026, commenced at 4:00 P.M. and concluded at 7:00 P.M. The decision to reschedule was communicated to BSE Limited pursuant to Regulation 30(6) of the SEBI (LODR) Regulations, 2015. The intimation was signed by Keyur Dipakkumar Shah, Managing Director of Dipna Pharmachem Ltd.

The audited financial results for the half year and year ended March 31, 2026, along with the Auditor's Report, are key items on the agenda. The outcome of the meeting will provide insights into the company's financial performance for the reported periods. Shareholders and investors are advised to await the official announcement post-meeting.

Meeting Details

The company has ensured compliance with regulatory requirements by intimating the exchange about the rescheduling. The audited financial results, once approved, will be disclosed in accordance with applicable regulations.